Objective:To study the clinical effect of uremic secondary hyperparathyroidism with hemodialysis and perfusion therapy. Methods:randomly selected in 2012 February~45 uremic secondary hyperparathyroidism patients in this hospital admissions in 2013 June as the research object, wil accept the low calcium dialysate and active Vitamin D3 shock treated patients (23 cases) classified as the control group, 22 cases in the control group based on the increase of HA type resin hemoperfusion therapy patients were classified as the observation group. Results:after the treatment, the patients in observation group were Ca (Xue Gai), P (phosphorus), iPTH (parathyroid hormone) and Ca*P (calcium phosphorus product) to improving the overal situation as control group;the observation group patients after the treatment of 18 cases of myasthenia gravis (81.8%), skin itching can be effectively al eviated, 11 cases in the control group (47.8%). Conclusion:the therapeutic effect of hemodialysis and perfusion flow in treatment of uremic secondary hyperparathyroidism is significant, worthy of clinical application.
hyperparathyroidismhemodialysis combined with hemoperfusionuremia
NETL
NSTL
万方数据
